Home › Prostate Cancer › North Dakota › Bismarck
Prostate Cancer clinical trials in Bismarck, ND
3 studies for Prostate Cancer are looking for participants at sites in and around Bismarck (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
RecruitingPhase 3
- Sanford Bismarck Medical Center, Bismarck
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
RecruitingPhase 3
- Sanford Bismarck Medical Center, Bismarck
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Sanford Bismarck Medical Center, Bismarck
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY103 studies
- Houston, TX76 studies
- Los Angeles, CA61 studies
- Boston, MA59 studies
- St. Louis, MO46 studies
- Chicago, IL45 studies
- San Francisco, CA45 studies
- Philadelphia, PA44 studies
- Baltimore, MD43 studies
- Nashville, TN42 studies
- Seattle, WA42 studies
- Washington, DC38 studies
Other studies in Bismarck
- Lung Cancer9 studies
- Non-Small Cell Lung Cancer6 studies
- Head and Neck Squamous Cell Carcinoma5 studies
- Colorectal Cancer3 studies
- Kidney Cancer (Renal Cell Carcinoma)3 studies
- Melanoma3 studies
- Hypopharyngeal Cancer3 studies
- Laryngeal Cancer3 studies
- Oral Cancer3 studies
- Pancreatic Cancer3 studies
- Colon Cancer3 studies
- Rectal Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.